NRC Stock Overview A commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Neuronetics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Neuronetics Historical stock prices Current Share Price US$1.28 52 Week High US$4.40 52 Week Low US$0.56 Beta 2.26 1 Month Change 49.47% 3 Month Change 87.94% 1 Year Change -47.19% 3 Year Change -64.58% 5 Year Change -67.73% Change since IPO -91.51%
Recent News & Updates Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
Third quarter 2024 earnings released: US$0.44 loss per share (vs US$0.33 loss in 3Q 2023) Nov 14
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 14
Neuronetics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 30
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 06
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05 See more updates Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
Third quarter 2024 earnings released: US$0.44 loss per share (vs US$0.33 loss in 3Q 2023) Nov 14
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 14
Neuronetics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 30
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 06
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults Sep 20
Independent Chairman of the Board recently bought €68k worth of stock Sep 16
Insufficient new directors Sep 01
Independent Chairman of the Board recently bought €53k worth of stock Aug 19
Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.17 loss in 2Q 2023) Aug 13 Neuronetics, Inc. (NasdaqGM:STIM) entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $1 million.
Neuronetics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 29
Neuronetics, Inc. Announces Aetna Policy Update Expands TMS Availability for Adolescents with Depression Jul 23
Independent Chairman of the Board recently bought €94k worth of stock Jun 10
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents May 16 Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024 May 09
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.38 loss in 1Q 2023) May 08
Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation Apr 11
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Mar 07
Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022) Mar 05
President recently sold €66k worth of stock Feb 27
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 22
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 21
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System Feb 12
President recently sold €55k worth of stock Jan 15
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023 Jan 09
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory Dec 19
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan Dec 05
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan Dec 04
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Nov 09
Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.28 loss in 3Q 2022) Nov 09
Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal Sep 14 Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023
Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.39 loss in 2Q 2022) Aug 09 Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans Jul 22
Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy Jun 13
First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.41 loss in 1Q 2022) May 11
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023 May 10
Executive VP recently sold €55k worth of stock Mar 16
Full year 2022 earnings released: US$1.38 loss per share (vs US$1.22 loss in FY 2021) Mar 08
President recently sold €200k worth of stock Feb 19
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer Feb 17
High number of new directors Feb 16
High number of new directors Feb 01
Senior VP recently sold €91k worth of stock Jan 21
Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health Jan 19
Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022 Jan 10
Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023 Dec 30
Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System Nov 15
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.31 loss in 3Q 2021) Nov 09
Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform Sep 27
Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022 Aug 27
Second quarter 2022 earnings released: US$0.39 loss per share (vs US$0.29 loss in 2Q 2021) Aug 03
Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022 Aug 03
President recently sold €232k worth of stock Jul 21 Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression
Cannell Capital LLC Communicates with Neuronetics Inc Jun 23
First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.31 loss in 1Q 2021) May 13
Neuronetics, Inc. Provides Earning Guidance for the Second Quarter and Full Year of 2022 May 13
Neurostar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder May 12
High number of new directors May 02
Neuronetics, Inc., Annual General Meeting, May 26, 2022 Apr 16 Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022 Mar 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Neuronetics, Inc. Announces the Commercial Launch of the MT Cap in the U.S Mar 03
Neuronetics, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Feb 24
Senior VP recently sold €56k worth of stock Jan 28
Neuronetics, Inc. Updates Earnings Guidance for the Fourth Quarter and Full Year of 2021 Jan 12
Neuronetics, Inc. Announces 510(k) Clearance of MT Cap Technology for NeuroStar Advanced Therapy for Mental Health Dec 21
Independent Chairman of the Board recently bought €55k worth of stock Nov 29
Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2020) Nov 10
Neuronetics, Inc Announces New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS Sep 23
Independent Chairman of the Board recently bought €85k worth of stock Sep 02
Second quarter 2021 earnings released: US$0.29 loss per share (vs US$0.41 loss in 2Q 2020) Aug 05
Senior VP recently sold €73k worth of stock Aug 01
President recently sold €581k worth of stock Jul 21
Independent Chairman Brian Farley has left the company Jun 05
Independent Director recently sold €77k worth of stock Jun 03
First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.68 loss in 1Q 2020) May 05
Neuronetics Reports revenue guidance for the year 2021 May 05
Neuronetics to Present Clinical Data At the American Psychiatric Association 2021 Annual Meeting Apr 30
Senior VP recently sold €105k worth of stock Mar 17
Neuronetics Enhances TrakSta Cloud Patient Data Management System to Maximize Physician Efficiencies Mar 11 Shareholder Returns NRC DE Medical Equipment DE Market 7D 15.6% -0.6% -0.2% 1Y -47.2% -8.4% 7.0%
See full shareholder returns
Return vs Market: NRC underperformed the German Market which returned 7% over the past year.
Price Volatility Is NRC's price volatile compared to industry and market? NRC volatility NRC Average Weekly Movement 22.6% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NRC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NRC's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Show more Neuronetics, Inc. Fundamentals Summary How do Neuronetics's earnings and revenue compare to its market cap? NRC fundamental statistics Market cap €41.33m Earnings (TTM ) -€34.93m Revenue (TTM ) €69.74m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NRC income statement (TTM ) Revenue US$72.71m Cost of Revenue US$15.77m Gross Profit US$56.94m Other Expenses US$93.36m Earnings -US$36.42m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.20 Gross Margin 78.31% Net Profit Margin -50.09% Debt/Equity Ratio 490.4%
How did NRC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 00:47 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Neuronetics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Gorman BTIG William Plovanic Canaccord Genuity David Turkaly JMP Securities
Show 3 more analysts 
